GLP-1 therapies face marketing, adherence and online prescription challenges

Pharmaceutical companies marketing GLP‑1 receptor agonists confront a shifting landscape. In Germany, manufacturers must manage lingering supply volatility, a reimbursement gap for obesity treatment, counterfeit‑risk concerns and a social‑media‑driven hype that blurs the line between legitimate promotion and influencer marketing. Transparent communication about availability and safety is being advocated to preserve patient trust.

New clinical data suggest that GLP‑1 agents such as semaglutide may have disease‑modifying effects beyond weight loss. Research presented at the 2026 EULAR Congress indicates a potential to slow cartilage degradation in osteoarthritis by targeting the GLP‑1R‑AMPK‑PFKFB3 pathway, opening avenues for broader therapeutic use.

Real‑world evidence from a Kaiser Permanente Colorado study shows that roughly one‑third of patients stop GLP‑1 therapy within six months, most often because of adverse drug reactions, medication cost and non‑adherence. Discontinuation rates are higher among Asian, Native American and Pacific Islander patients and among those using the drugs solely for obesity.

A Yale‑led secret‑shopper investigation found that more than 90 % of 49 telehealth sites dispense GLP‑1 prescriptions—often without any clinician interaction—exposing consumers to safety risks and encouraging a gray market for compounded, unapproved products. High out‑of‑pocket prices (US $900‑$1,400) are a key driver of this bypass.

Patient reports from South Africa highlight mixed experiences with GLP‑1 injections, noting appetite suppression and weight loss benefits but also early therapy termination in some cases, underscoring the need for better patient education and support.